This site is intended for Healthcare Professionals only.

Novo Nordisk invests £1.8 bln in Danish production facility


Share post:

Hot on the heels of its popularity over weight-loss drug Wegovy, Danish drugmaker Novo Nordisk is to invest £1.8 billion to expand a production facility in Denmark for products to treat serious chronic diseases, the company said in a statement on Monday (June 12).

However, the company has clarified that the current expansion is not for the production of semaglutide, the key ingredient in Ozempic and Wegovy, which treat diabetes and weight-loss respectively.

The facility in Bagsvaerd, Denmark produces active pharmaceutical ingredient (API), the main biologically active components of medicines, and will be expanded to produce material for both current and future products.

Novo has faced major supply constraints of semaglutide after it was overwhelmed by massive demand for Wegovy during its launch in the United States in 2021, and has invested heavily to increase the supply.

Last month, the firm said it would ration the supply of starter doses for Wegovy in the U.S. to cope with demand.

Construction of the new facility is underway and it is expected to start producing API by early 2029.

“This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” Novo’s head of product supply, quality and IT, Henrik Wulff, said in a statement.


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

How pharmacists can help children and young people with asthma: 2024 AskAboutAsthma campaign highlights

The 2024 #AskAboutAsthma campaign calls on pharmacists to take an active role in improving asthma management and outcomes...

Huxley Europe relaunches HuxQ10 Capsules with triple certification

The relaunch underscores Huxley Europe's commitment to health and welfare, offering specially developed formulas for users with dietary...

Alastair Buxton outlines vision for Community Pharmacy at Westminster Health Forum

Alastair Buxton, Director of NHS Services at CPE, outlines critical issues and solutions at the Westminster Health Forum,...

Food prices remain UK consumers’ top concern, FSA report finds

Consumers worried about food affordability were more likely to take food safety risks to save money The Food...